Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update
Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain and plays an important role in inflammation.
The Non Receptor Tyrosine Protein Kinase TYK2 drugs in development market research report provides comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.
What are the key therapy areas in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market?
The key therapy areas in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market are immunology, gastrointestinal, musculoskeletal disorders, dermatology, oncology, central nervous system, infectious disease, metabolic disorders, and respiratory.
Non Receptor Tyrosine Protein Kinase TYK2 Pipeline Products Market Analysis by Therapy Area
For more therapy area insights, download a free report sample
What are the key indications in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market?
The key indications in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market are psoriasis, inflammatory bowel disease, systemic lupus erythematosus, ulcerative colitis, rheumatoid arthritis, Crohn’s disease (regional enteritis), plaque psoriasis (psoriasis vulgaris), atopic dermatitis (atopic eczema), autoimmune disorders, psoriatic arthritis, and others.
Non Receptor Tyrosine Protein Kinase TYK2 Pipeline Products Market Analysis by Indications
For more indication insights, download a free report sample
What are the key mechanisms of action in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market?
The key mechanism of action in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market is Non Receptor Tyrosine Protein Kinase TYK2 Inhibitor.
What are the key routes of administration in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market?
The key routes of administration in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market are oral, topical, ophthalmic, and intravitreal.
Non Receptor Tyrosine Protein Kinase TYK2 Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
What are the different molecule types in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market?
The molecule type in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market is small molecule.
Which are the major companies in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market?
Some of the major companies in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market are AbbVie Inc, Alexion Pharmaceuticals Inc, Amgen Inc, Atomwise Inc, Bristol-Myers Squibb Co, Esker Therapeutics Inc, Galapagos NV, Haisco Pharmaceutical Group Co Ltd, InnoCare Pharma Ltd, and Merck & Co Inc
Non Receptor Tyrosine Protein Kinase TYK2 Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Scope
Key therapy area | Immunology, Gastrointestinal, Musculoskeletal Disorders, Dermatology, Oncology, Central Nervous System, Infectious Disease, Metabolic Disorders, and Respiratory |
Key indications | Psoriasis, Inflammatory Bowel Disease, Systemic Lupus Erythematosus, Ulcerative Colitis, Rheumatoid Arthritis, Crohn’s Disease (Regional Enteritis), Plaque Psoriasis (Psoriasis Vulgaris), Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Psoriatic Arthritis, and Others |
Key mechanism of action | Non Receptor Tyrosine Protein Kinase TYK2 Inhibitor |
Key routes of administration | Oral, Topical, Ophthalmic, and Intravitreal |
Molecule type | Small Molecule |
Major companies | AbbVie Inc, Alexion Pharmaceuticals Inc, Amgen Inc, Atomwise Inc, Bristol-Myers Squibb Co, Esker Therapeutics Inc, Galapagos NV, Haisco Pharmaceutical Group Co Ltd, InnoCare Pharma Ltd, and Merck & Co Inc |
Scope
- The report provides a snapshot of the global therapeutic landscape of Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
- The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews the latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage
- Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
GDPR + CCPA Compliant
Personal and transaction information are kept safe from unauthorised use.